Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference James PhillipsMarch 12, 2024
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini James PhillipsMarch 4, 2024
Revelation Biosciences Inc. Receives Invitation to give an Oral Presentation at The 29th International James PhillipsFebruary 13, 2024
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering James PhillipsFebruary 5, 2024
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering James PhillipsFebruary 1, 2024
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) James PhillipsJanuary 30, 2024
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split effective January 25, 2024 James PhillipsJanuary 23, 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023 James PhillipsNovember 13, 2023
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies James PhillipsOctober 12, 2023
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference James PhillipsOctober 4, 2023
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors James PhillipsOctober 2, 2023
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023 James PhillipsAugust 11, 2023
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders James PhillipsJune 29, 2023
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal James PhillipsJune 12, 2023
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress James PhillipsMay 22, 2023
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board James PhillipsMarch 13, 2023
Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference James PhillipsMarch 6, 2023
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering James PhillipsFebruary 13, 2023
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering James PhillipsFebruary 9, 2023
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300 James PhillipsFebruary 7, 2023
